Inovio Pharmaceuticals
123 hedge funds and large institutions have $156M invested in Inovio Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 39 increasing their positions, 25 reducing their positions, and 12 closing their positions.
75% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 12
56% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 25
54% more call options, than puts
Call options by funds: $6.12M | Put options by funds: $3.98M
10% more capital invested
Capital invested by funds: $142M → $156M (+$14.1M)
8% more funds holding
Funds holding: 114 → 123 (+9)
0.19% less ownership
Funds ownership: 3.4% → 3.21% (-0.19%)
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$2.61M |
| 2 |
Millennium Management
New York
|
+$2.33M |
| 3 |
IG
ING Group
Amsterdam,
Netherlands
|
+$2.32M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$2.15M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.58M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$13.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.79M |
| 3 |
ARTA
A.R.T. Advisors
New York
|
-$1.65M |
| 4 |
RCM
Rotella Capital Management
Bellevue,
Washington
|
-$1.18M |
| 5 |
HCM
Highbridge Capital Management
New York
|
-$1.06M |
INO Hedge Fund Activity: Q4 2015 in Review
123 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q4 2015, worth a combined $156M — up 9.9% from $142M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new INO positions and 12 closed out — a net gain of 9 holders — while 39 added to existing stakes and 25 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $2.61M. The largest seller was State Street, cutting an estimated $13.2M.
- 123 institutional investors held Inovio Pharmaceuticals (INO) as of Q4 2015, up from 114 in Q3 2015.
- Funds reported $156M of Inovio Pharmaceuticals stock for Q4 2015, up 9.9% quarter-over-quarter.
- 21 funds opened new Inovio Pharmaceuticals positions in Q4 2015 and 12 closed out, a net change of +9 holders.
- The largest Inovio Pharmaceuticals buyer in Q4 2015 was Renaissance Technologies, an estimated $2.61M added.
- The largest Inovio Pharmaceuticals seller in Q4 2015 was State Street, an estimated $13.2M sold.
Based on aggregated 13F filings for Q4 2015.